메뉴 건너뛰기




Volumn 3, Issue 3, 2012, Pages 295-297

Current landscape and trends in transdermal drug delivery systems

Author keywords

drug delivery; generic patch; life cycle management; microneedles; pain; transdermal patch

Indexed keywords

ADRENALIN; CLONIDINE; EMLA; FENTANYL; GENERIC DRUG; LIDOCAINE; LIDOCAINE PLUS TETRACAINE; RIVASTIGMINE; SCOPOLAMINE;

EID: 84858119424     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.11     Document Type: Review
Times cited : (8)

References (8)
  • 1
    • 84858132176 scopus 로고    scopus 로고
    • Profiles of recently approved transdermal drug delivery systems (TDDS). Part 1: Exelon patch-example of life cycle strategy for successful products; Generic clonidine transdermal systems-design and delivery attributes
    • Yeoh T. Profiles of recently approved transdermal drug delivery systems (TDDS). Part 1: Exelon patch-example of life cycle strategy for successful products; generic clonidine transdermal systems-design and delivery attributes. TransDermal Mag. 3(4), 10-17 (2011).
    • (2011) TransDermal Mag. , vol.3 , Issue.4 , pp. 10-17
    • Yeoh, T.1
  • 2
    • 84858148471 scopus 로고    scopus 로고
    • Profiles of recently approved transdermal drug delivery systems (TDDS). Part II: Matrix-type fentanyl transdermal systems-design variation and delivery attributes
    • Yeoh T. Profiles of recently approved transdermal drug delivery systems (TDDS). Part II: Matrix-type fentanyl transdermal systems-design variation and delivery attributes. TransDermal Mag. 3(5), 9-15 (2011).
    • (2011) Trans Dermal Mag. , vol.3 , Issue.5 , pp. 9-15
    • Yeoh, T.1
  • 3
    • 85157124374 scopus 로고    scopus 로고
    • Reduction of pain associated with minor procedures in children-new topical anesthetics on the horizon
    • Zempsky WT. Reduction of pain associated with minor procedures in children-new topical anesthetics on the horizon. Touch Briefings. Business Briefing: US pediatric Care. 19-22 (2005).
    • (2005) Touch Briefings. Business Briefing: US Pediatric Care , pp. 19-22
    • Zempsky, W.T.1
  • 4
    • 85157154332 scopus 로고    scopus 로고
    • Joining the transdermal pipeline
    • Hill L. Joining the transdermal pipeline. TransDermal Mag. 3(4), 5-8 (2011).
    • (2011) Trans Dermal Mag. , vol.3 , Issue.4 , pp. 5-8
    • Hill, L.1
  • 5
    • 23044491985 scopus 로고    scopus 로고
    • Keynote review: Is declining innovation in the pharmaceutical industry a myth?
    • DOI 10.1016/S1359-6446(05)03524-5, PII S1359644605035245
    • Schmid EF, Smith DA. Is declining innovation in the pharmaceutical industry a myth? Drug Discov. Today 10(15), 1031-1039 (2005). (Pubitemid 41074141)
    • (2005) Drug Discovery Today , vol.10 , Issue.15 , pp. 1031-1039
    • Schmid, E.F.1    Smith, D.A.2
  • 6
    • 84858146404 scopus 로고    scopus 로고
    • Guidance for industry US, Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), August
    • Guidance for industry. Residual Drug in Transdermal and Related Drug Delivery Systems. US, Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), August 2011.
    • (2011) Residual Drug in Transdermal and Related Drug Delivery Systems
  • 7
    • 44749091856 scopus 로고    scopus 로고
    • Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?
    • Lamberta PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine, 26, 26, 3197-3208 (2008).
    • (2008) Vaccine , vol.26 , Issue.26 , pp. 3197-3208
    • Lamberta, P.H.1    Laurent, P.E.2
  • 8
    • 79954529447 scopus 로고    scopus 로고
    • Analysis of new FDA draft guidances: Insights on study designs for bioequivalence assessment of transdermal systems
    • Lehman PA. Analysis of new FDA draft guidances: insights on study designs for bioequivalence assessment of transdermal systems. Drug Develop. Deliv. 11(3), 36-41 (2011).
    • (2011) Drug Develop. Deliv. , vol.11 , Issue.3 , pp. 36-41
    • Lehman, P.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.